Answer
Periodic skin examinations are recommended for all patients using Opzelura (ruxolitinib) cream, particularly those with skin cancer risk factors, because non-melanoma skin cancers, predominantly basal cell carcinomas, have been reported, although a causal relationship has not been established.
Sources for this answer
- Opzelura 15 mg/g creamIncyte Biosciences UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked